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Abstract: Focused on our interest to develop novel antiparasistic agents, the present study was aimed
to evaluate the biological activity of an extract of Laurencia johnstonii collected in Baja California
Sur, Mexico, against an Acantamoeba castellanii Neff strain. Bioassay-guided fractionation allowed
us to identify the amoebicidal diastereoisomers α-bromocuparane (4) and α-isobromocuparane (5).
Furthermore, bromination of the inactive laurinterol (1) and isolaurinterol (2) yielded four
halogenated derivatives, (6)–(9), which improved the activity of the natural sesquiterpenes. Among
them, the most active compound was 3α-bromojohnstane (7), a sesquiterpene derivative which
possesses a novel carbon skeleton johnstane.
Keywords: brominated sesquiterpene; marine natural products; Laurencia johnstonii; johnstane;
3-bromojohnstane; anti-amoeboid activity; Acanthamoeba
1. Introduction
Free-living amoeba (FLA) are widely distributed protozoa in the environment [1–3]. These
parasites present a life cycle with two different stages: the trophozoite and the resistant phase,
the cyst. Among FLA, Acanthamoeba genus [4] has been isolated from air, soil, water, contact lenses, air
conditioning units, clinical samples, among others [5]. These parasites are able to cause pathologies
in humans such as Granulomatous Amoebic Encephalitis (GAE) and Amoebic Keratitis (AK) [1–3,5].
Regarding Acanthamoeba infections, an early diagnosis is crucial to achieve a successful treatment [3,6].
Antimicrobial chemotherapy is the most widely used method for treating Acanthamoeba-caused
infections. Pentamidine, azoles, sulfonamides, and possibly flucytosine, are among the most frequently
used drugs in successfully treated cases of GAE, whereas topical chlorhexidine or polyhexamethylene
biguanide appear to be the most effective option in cases of AK [7]. However, the existing therapies
are not fully effective against these organisms mainly due to the existence of the cyst phase, and also
due to the presence of strains that are resistant to the currently used anti-amoebic drugs [2,3,8].
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In the past, natural products have been used for the treatment of different parasitic diseases.
Artemisinin, quinine, amphotericin B, and ivermectin are examples of important antiparasitic
compounds isolated from plants and microorganisms [9,10]. From 1981 to 2014, 15 small molecules
were approved as antiparasitic drugs; among them, two were obtained from natural sources and
five are the result of semisynthetic derivatives of natural products [11], however, none of them
came from marine sources. Many other natural products of diverse molecular structures have
revealed antiparasitic potency in the laboratory and, thus, represent interesting lead structures for the
development of new and urgently needed antiparasitic agents.
The genus Laurencia is one of the richest sources of novel secondary metabolites among red
algae [12–15]. Although the chemistry of Laurencia species has been exhaustively investigated,
the biological activity of the isolated secondary metabolites has not been studied in a systematic
way. Furthermore, Laurencia metabolites have been revealed to possess antiparasitic properties against
a number of parasites and their vectors. However, no activity has been previously reported against
Acanthamoeba [10,16].
Focused on our interest to develop novel lead structures for the development of antiparasistic agents,
the present study was aimed to evaluate the biological activity of an extract of Laurencia johnstonii against
an Acanthamoeba castellanii Neff strain. To the best of our knowledge, johnstonol [17] and prepacifenol
epoxide [18] are the only sesquiterpenes isolated from specimens of Laurencia johnstonii, both with
a chamigrene carbon skeleton. In this paper, we report the isolation of the known brominated
metabolites laurinterol (1), isolaurinterol (2), aplysin (3), and the antiparasitic diastereoisomers
α-bromocuparane (4) and α-isobromocuparane (5), with cyclolaurane, laurane and cuparane
backbones. (Figure 1). In addition, transformation of (1) and (2) has yielded four structural derivatives
(6–9) which improved the antiparasitic activity with respect to the natural products.
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seven subfractions. The most active was SF3.1 (n-hexane fraction) with an IC50 value of 101.29 ± 0.2 
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Figure 1. Struct res of natural sesquite (1)–(5) isolated from Laurencia jonhstonii.
2. Results and Discussion
2.1. Isolation and Identification of Natural Brominated Sesquiterpenes
Laurencia johnstonii was collected of the c f the Gulf of California, Mexico. Clean and dry
specim ns were extracted in ethanol to give a crude extract which showed m derate anti-Acanthamoeba
activity with an IC50 alue of 125.14 ± 4.5 µg/mL. The bioassay-guided fractionation of the ethanolic
extract by Sephadex LH-20 led us to an active fraction (SF3). This fraction was further chromatographed
over a silica gel column using a step-gradient from n-hexane to EtOAc to give seven subfractions.
The most active was SF3.1 (n-hexane fraction) with an IC50 value of 101.29 ± 0.2 µg/mL. After
a separation on a silica gel open column eluted with mixtures of n-hexane:EtOAc, fraction SF3.1
yielded aplysin (3) [19], and the active stereoisomers α-bromocuparane (4) and α-isobromocuparane
(5) [20], which showed activity against Acanthamoeba castellanii Neff with IC50 values of 90.68 ± 1.5
and 64.25 ± 1.5 µg/mL, resp ctively. Additionally, laurinterol (1) [21], and isolaurinterol (2) [22] were
isolated from the inactive fraction SF3.2. The NMR, mass pectrometry, and optical rotation data of
(1)–(5) were compared with those previously reported in the literature to confirm their structures
(Supplementary Materials).
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2.2. Derivatization of Laurinterol (1) and Isolaurinterol (2)
Halogenation is a common biosynthetic strategy found in marine organisms as is the case of
Laurencia species [23]. Halogen-containing natural products display a wide range of biological activities;
therefore, they are interesting structures for medicinal chemistry studies. The presence of halogen
substituents in many natural products also enhances their biological activities [24]. In order to evaluate
structure−activity relationships of laurinterol and its congeners in antiparasitic assays, bromination of
(1) and (2) were carried out to obtain their brominated derivatives. Hence, laurinterol (1) was dissolved
in ethyl ether and treated with bromine. The reaction mixture was chromatographed on a silica gel
column to obtain the brominated sesquiterpene derivatives (6) and (7) (Figure 2).
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Comp und (6) was obtained as colorless oil. Its molecular for l t blished by HR-EI-MS
(High-Resolution Electron Impact Mass Spectrometry) analysis as C15H18Br2O by the presence of three
molecular ions [M]+ at m/z 371.9711/373.9702/375.9677 (calcd. 371.9724/373.9704/375.9683; ratio
50:100:48), indicative of two bromine atoms and six degrees of unsaturation. The structure of (6) was
determined by comparison of its NMR data with those for aplysin (3) (Table 1). The main differences
observed in their 1H NMR spectra were the absence of one of the two aromatic singlets of (3), H-8
(δH 6.59), and a deshielded aromatic methyl group H3-15 (δH 2.49) for (6) compared with that of 3
H3-15 (δH 2.30). These values agree with the presence of a bromine atom at C-8 in the aromatic ring as
well as with the information provided by mass spectrometry.
Table 1. 1H and 13C NMR data for aplysin (3) and (6) (600 MHz, 150 MHz, CDCl3).
Position
Aplysin (3) 6
δC, Type δH (J in Hz) δ , Type δH (J in Hz)
1 54.3, C 56.0, C
2 99.8, C 100.5, C
3 46.0, CH 1.75, ddd (12.8, 6.9, 6.5) 46.4, CH 1.79, ddd (13.3, 6.5, 6.5)
4 31.1, CH2
1.62, m 31.3, CH2
1.65, m
1.15, m 1.15, m
5 42.5, CH2
1.85, dd (6.4, 12.1) 42.7, CH2
1.86, dd (12.1, 6.2)
1.58, d (6.2) 1.64, ddd (12.1, 6.2, 6.2)
6 136.2, C 136.2, C
7 158.1, C 156.0 1, C
8 110.8, CH 6.59, s 105.1, C
9 136.9, C 136.0, C
10 113.9, C 114.1, C
11 126.5, CH 7.14, s 125.4, CH 7.11, s
12 13.0, CH3 1.10, d (6.8) 13.3, CH3 1.14, d (6.8)
13 23.1, CH3 1.30, s 20.4, CH3 1.34, s
14 23.3, CH3 1.29, s 23.2, CH3 1.32, s
15 29.9, CH3 2.30, s 23.5, CH3 2.49, s
1 Chemical shift deduced from the HMBC experiment.
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Aplysin (3) was easily obtained after treatment of laurinterol (1) with HBr (Figure 2). The specific
rotations for (1) ([α]25D +17) and 3 ([α]
25
D −49) are consistent with those reported in the literature for
both compounds (1): [α]25D +13 and 3: [α]
25
D −86, for which the absolute configuration was stablished
by X-ray crystallography [21,25]. According to this, and supported by consistent chemical shifts and
coupling constants of H3-12, H3-13, H3-14 and H-3 between 6 and aplysin (3) (Table 1), the absolute
configurations of 6 are 1S, 2S, and 3S. Caccamese and Rinehart identified 6 as bromoaplysine in 1978
by GC-MS [26]. Later, in 2010, a patented methodology for the extraction of antiobesity sesquiterpenes
from Laurencia species [27] refers 6 as 8-bromoaplysin, however no complete NMR data has been
reported for this brominated sesquiterpene.
Compound 7 was obtained as a colorless oil. The HREIMS analysis provided four molecular ions
[M]+ at m/z 449.8840/451.8800/453.8798/455.8758 (calcd. 449.8829/451.8809/453.8789/455.8768; ratio
26:78:67:26) suggesting a molecular formula C15H17OBr3 and six degrees of unsaturation. The structure
of 7 was established based on the analysis of its spectroscopic data and comparison with those of 6.
1D and 2D NMR spectra evidenced three methyl, three methylenes, and two methine groups (one on
sp2 carbon and one bearing heteroatom), in addition to five sp2 and two sp3 quaternary carbons.
Similar to 6, the pentasubstituted phenyl ring was confirmed by the presence of a singlet at δH 7.14
(H-12) and the methyl group at δH 2.53 (H3-15) in the 1H NMR spectrum (Table 2), and the HMBC
correlations from H3-13 (δH 2.54, s) and H3-14 (δH 1.04, s) to a quaternary carbon at δC 92.3 (C-2),
and from H3-14 to C-7 (δC 136.3) confirming the presence of the same dihydrofuran ring found
in 6. The main difference between both compounds was a COSY spin system from the diasterotopic
protons H2-3 (δH 2.42/1.99), sequentially coupled with the bromomethine H-4 (δH 3.84), methylene
H2-5 (δH 2.18/1.76), and methylene H2-6 (δH 2.18/1.54). HMBC correlations from H3-14 (δH 1.04) to
C-6 (δC 32.8) and H3-13 (δH 2.54) to C-3 (δC 47.6) led to the connection of this substructure within
the molecule and thus established the planar structure of the rearranged sesquiterpene 7 as shown
in Figure 3.
Table 2. NMR data for 3α-bromojohnstane (7) (600 MHz, 150 MHz, CDCl3).
Position
3α-Bromojohnstane (7)
δC, Type δH (J in Hz)
1 48.1, C
2 92.3, C
3 47.6, CH2
β: 2.42 dd (3.6, 12.9)
α: 1.99 dd (12.6, 12.9)
4 45.8, CH 3.84 dddd (3.6, 3.6, 12.3, 12.6)
5 34.2, CH2
β: 2.18 dddd (3.2, 3.5, 3.6, 12.9)
α: 1.76 dddd (3.5, 12.3, 12.3, 12.6)
6 32.8, CH2
β: 1.54 ddd (3.5, 12.3, 12.9)
α: 2.18 ddd (3.2, 3.5, 12.9)
7 136.3, C
8 155.3, C
9 107.6, C
10 136.6, C
11 115.5, C
12 124.6, CH 7.14 s
13 19.7, CH3 1.54 s
14 26.7, CH3 1.04 s
15 23.3, CH3 2.53 s
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NOE correlations observed from H3-13 to H3-14 and H-4, and from H-4 to the diastereotopic
proton H-3β located all these protons on the same face of the molecule. Since the absolute configuration
of laurinterol (1) has been confirmed and configuration at C-1 is conserved in 7, it is possible to establish
the absolute configuration of its chiral centers as 1S, 2S, and 4S.
In 1972, Yamada et al. reported the synthesis of 2,3-dimethyl-3-(5-bromo-2-methoxy-4-methylphenyl)
-cyclohexane from an anisole derivative as a key intermediate to obtain aplysin (3) and other related
sesquiterpenes [28]. Also, synthetic efforts to obtain the sesquiterpene cuparene through radical
cyclization exclusively yielded 1-(1,2-dimethylcyclohexyl)-4-methylbenzene [29].
It is noteworthy that, even though chemical investigations on the prolific genus Laurencia have
yielded over 500 sesquiterpene metabolites belonging to more than 50 carbon frameworks [16], so far
none has been reported to possess that of 7. Thus, for this carbon backbone we propose the name
johnstane and the name 3α-bromojohnstane for 7 (Figure 4).
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In the same way, isolaurinterol (2) was dissolved in ethyl ether and treated with bromine to
afford 6, and the known sesquiterpenes 8,10-dibromoisoaplysin (8) [30] as well as the 13-hydroxy
derivative 9, also obtained after bromination of debromoaplysinol [31].
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2.3. Antiparasitic Effect Against Acanthamoeba Castellanii Neff Strain
As well as in the case of natural sesquiterpenes 1–5, the antiamoeboid activity of the brominated
sesquiterpene derivatives 6–9 was tested against Acanthamoeba castellanii Neff (Inhibitory Concentrations
(IC50) shown in Table 3). Moreover, their toxicity (Cytotoxic Concentrations (CC50) at 24 h, Table 3) against
murine macrophages J774.A1 (ATCC # TIB-67) at 24 h was evaluated as previously described [32,33].
Table 3. Effect of Laurencia johnstonii ethanolic extract and 1–9 against Acanthamoeba castellanii Neff
(IC50) and murine macrophage J774.A1 (CC50). * Reference compounds.
Sample IC50 (µg/mL) IC50 (µM) CC50 (µg/mL)
Crude extract 125.14 ± 4.5 n/d
1 >100 23.65 ± 2.3
2 >100 7.25 ± 0.7
3 >100 323.69 ± 12.0
4 90.674 ± 1.529 322.41 ± 5.44 33.04 ± 4.2
5 64.251 ± 3.492 228.46 ± 12.42 85.34 ± 10.9
6 24.559 ± 1.105 65.64 ± 2.95 32.880 ± 3.125
7 18.804 ± 0.198 41.51 ± 0.44 62.341 ± 2.589
8 22.818 ± 1.896 50.37 ± 4.19 70.365 ± 3.245
9 29.937 ± 2.918 76.74 ± 7.48 74.931 ± 2.769
Chlorhexidine * 1.526 ± 0.45 3.02 ± 0.89 6.64 ± 0.35
Voriconazole * 0.33 ± 0.1 0.94 ± 0.29 2.64 ± 0.27
As shown in Table 3, all brominated derivatives (6–9) improved the activity of the natural
sesquiterpenes (1–5). Monobrominated compounds in the aromatic ring, 1–3, were inactive, thus
suggesting that dibromination of the aromatic moiety is relevant to obtain antiamoeboid activity.
On the other hand, natural diastereoisomers 4 and 5, which only differ in the configuration of the
bromine atom attached to C-3 of cyclopentane ring, showed a differentiated activity. It is interesting
to note that an α-oriented bromine substitution at C-3 in 5 increases the activity against A. castellanii
while decreases the toxicity, a structural feature also found in compound 7. 3α-bromojohnstane (7)
was the most active molecule against A. castellanii with an IC50 value of 41.51 µM, and one of those
with lower toxicity values against murine macrophages among the assayed compounds.
3. Materials and Methods
3.1. General Experimental Procedures
Optical rotations were measured in CH2Cl2 on a PerkinElmer 241 polarimeter (Waltham, MA,
USA), by using a sodium lamp operating at 589 nm. NMR spectra were recorded on a Bruker AVANCE
500 MHz or 600 MHz, as required. NMR spectra were obtained dissolving samples in CDCl3 (99.9%)
and chemical shifts are reported relative to solvent (δH 7.26 and δC 77.0 ppm) and TMS as internal
pattern. Bruker AVANCE 600 MHz instrument is equipped with a 5 mm TCI inverse detection
cryoprobe. Standard Bruker NMR pulse sequences were utilized. HR-ESI-MS (High-Resolution
ElectroSpray Ionization Mass Spectrometry) and HR-EI-MS (High-Resolution Electron Impact Mass
Spectrometry) data were obtained on a Waters LCT Premier XE Micromass (Manchester, UK) and
VG-AutoSpec Micromass (Manchester, UK) spectrometers, respectively. IR spectra were recorded
on a Bruker IFS66/S (Ettlingen, Germany) equipped with an ATR accessory using CH2Cl2 solutions.
EnSpire® Multimode Reader (Perkin Elmer, Walt, MA, USA) using absorbance values of Alamar Blue®
reagent. TLC (Thin layer chromatography) (Merck, Darmstadt, Germany) was visualized by UV light
(254 nm) and spraying with cobalt chloride reagent (2% in sulfuric acid, 10%) and heating.
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3.2. Biological Material
Laurencia johnstonii was collected by hand during June–July 2015 off the coast of Baja California
Sur, Mexico (24◦21′10.8′ ′ N, 110◦16′58.8′ ′ W). A voucher specimen (code 13-003) was deposited at the
Herbarium of the Laboratory of Marine Algae of the CICIMAR (Centro Interdisciplinario de Ciencias
Marinas, Mexico). This seaweed was identified to genus and species level by Dr. Rafael Riosmena
Rodríguez (Universidad Autónoma de Baja California Sur) using taxonomic keys for future reference.
3.3. Extraction and Isolation
Specimens of Laurencia johnstonii were cleaned of sand and epiphytes, and dried. Dried alga
was crushed using a blender and extracted with EtOH for three days at 25 ◦C under gentle agitation.
The EtOH was replaced (3 × 1200 mL), and the combined extracts were filtered through a Whatman
no. 4 filter paper. Solvent was removed using a rotatory vacuum evaporator. 10.0 g of the resulting
extract were chromatographed in Sephadex LH-20 (Sigma, St. Louis, MO, USA) (500× 70 mm, CH3OH,
100%) to obtain five fractions. The active fraction SF3 was separated in flash Silicagel 0.2–0.5 mm
(Sigma-Aldrich, St. Louis, MO, USA) (130 × 70 mm) using a stepwise gradient of n-hexane: ethyl
acetate to obtain 7 fractions. Fractions SF3.1 (100% n-hexane) and SF3.2 (95% n-hexane) were separated
on a normal phase open column (Silicagel, 0.2–0.5 mm, 300 × 50 mm, using a stepwise gradient of
n-hexane: ethyl acetate) to yield pure compounds 5 (10.5 mg), 4 (7.2 mg) and 3 (45.9 mg) from SF3.1 and
compounds 3 (10.2 mg), 2 (8.1 mg) and 1 (55.7 mg) from SF3.2. (Supplementary Materials, Scheme S1)
3.3.1. Laurinterol (1)
White crystal; [α]25D +17 (c 0.15, CH2Cl2); HRESIMS m/z 293.0531 [M − H]− (calc. C15H18O79Br,
293.0541), 295.0518 [M − H]− (calc. C15H18O81Br, 295.0521) 1H NMR (500 MHz, CDCl3) δ 0.55 (1H, dd,
J = 7.9, 4.8 Hz, H-12), 0.58 (1H, t, J = 4.6 Hz, H-12), 1.15 (1H, dt, J = 8.1, 4.3 Hz, H-3), 1.28 (1H, m, H-5),
1.32 (3H, s, H-13), 1.41 (3H, s, H-14), 1.66 (1H, dd, J = 12.3, 8.0 Hz, H-4), 1.95 (1H, tdd, J = 12.3, 8.1, 4.4,
H-4), 2.09 (1H, dd, J = 13.2, 8.1 Hz, H-5), 2.29 (3H, s, H-15), 5.26 (1H, br, s, 7-OH), 6,61 (1H, s, H-8),
7.61 (1H, s, H-11); 13C NMR (125 MHz, CDCl3) δ 16.2 (C-12), 18.6 (C-13), 22.2 (C-14), 23.5 (C-15), 24.4
(C-3), 25.3 (C-4), 29.6 (C-2), 35.9 (C-5), 114.9 (C-10), 118.8 (C-8), 132.3 (C-11), 134.0 (C-6), 135.9 (C-9),
153.3 (C-7).
3.3.2. Isolaurinterol (2)
Colorless amorphous solid; [α]25D −46 (c 0.14, CH2Cl2); HRESIMS m/z 293.0536 [M − H]− (calc.
C15H18O79Br, 293.0541), 295.0528 [M − H]− (calc. C15H18O81Br, 295.0521) 1H NMR (500 MHz, CDCl3)
δ 1.21 (3H, d, J = 7.0 Hz, H-12), 1.42 (1H, ddd, J = 12.8, 8.2, 6.6 Hz, H-5), 1.46 (3H, s, H-14), 1.59 (1H, dt,
J = 12.9, 7.1, 7.1 Hz, H-4), 2.05 (1H, ddt J = 12.8, 8.5, 7.0, 7.0 Hz, H-3), 2.20 (1H, ddd, J = 13.0, 8.1 6.7 Hz,
H-4), 2.31 (3H, s, H-15), 2.85 (1H, ddt, J = 9.1, 6.9, 6.9, 2.3, 2.3 Hz, H-5), 4.94 (1H, d, J = 2.2 Hz, H-13),
5.11 (1H, d, J = 2.2 Hz, H-13), 5.56 (1H, br, s, 7-OH), 6.73 (1H, s, H-8), 7.45 (1H, s, H-11); 13C NMR
(125 MHz, CDCl3) δ 21.2 (C-14), 22.2 (C-15), 27.8 (C-12), 31.2 (C-4), 37.6 (C-3), 39.1 (C-5), 49.8 (C-1),
106.9 (C-13), 115.5 (C-10), 120.4 (C-8), 131.2 (C-11), 132.7 (C-6), 137.2 (C-9), 153.0 (C-7), 165.4 (C-2).
3.3.3. Aplysin (3)
Colorless needles; [α]25D −49 (c 0.19, CH2Cl2); HRESIMS m/z 293.0551 [M−H]− (calc. C15H18O79Br,
293.0541), 295.0529 [M −H]− (calc. C15H18O81Br, 295.0524). 1H and 13C NMR data (Table 1).
3.3.4. α-Bromocuparane (4)
White amorphous solid; [α]25D +21 (c 0.19, CH2Cl2); HREIMS [M − H]+ m/z 279.0744 (calc. for
C15H2079Br, 279.0748), 282.0723 (calc. for C15H2081Br, 282.0728), [M − Br]+ m/z 201.1640 (calc. for
C15H21, 201.1643); 1H NMR (500 MHz, CDCl3) δ 0.62 (3H, s, H-13), 1.09 (3H, s, H-12), 1.43 (3H, s, H-14),
1.96 (1H, m, H-5), 2.24 (1H, m, H-4), 2.27 (1H, m, H-5), 2.32 (3H, s, H-15), 2.52 (1H, ddt, J = 14.3, 9.3, 5.2,
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H-4), 4.07 (1H, t, J = 9.4 Hz, H-3), 7.09 (4H, m, H-7, H-8, H-10, H-11); 13C NMR (125 MHz, CDCl3) δ
20.7 (C-15), 20.9 (C-13), 22.4 (C-12), 25.0 (C-14), 33.1 (C-4), 36.4 (C-5), 47.4 (C-2), 48.4 (C-1), 62.0 (C-3),
127.3 (C-7, C-11), 128.1 (C-8, C-10), 135.4 (C-9), 143.9 (C-6).
3.3.5. α-Isobromocuparane (5)
Colorless oil; [α]25D +37 (c 0.14, CH2Cl2); HREIMS [M]
+ m/z 280.0826 (calc. for C15H2179Br,
280.0827), 282.0801 (calc. for C15H2181Br, 282.0806), [M− Br]+ m/z 201.1649 (calc. for C15H21, 201.1643);
1H NMR (500 MHz, CDCl3) δ 0.65 (3H, s, H-13), 1.10 (3H, s, H-12), 1.28 (3H, s, H-14), 1.61 (1H, m, H-5),
2.20 (1H, m, H-4), 2.33 (3H, s, H-15), 2.51 (1H, dtd, J = 14.2, 9.5, 6.5 Hz, H-4), 2.71 (1H, td, J = 12.6,
6.4 Hz, H-5), 4.46 (1H, t, J = 9.2 Hz, H-3), 7.12 (1H, d, J = 8.1 Hz, H-10), 7.13 (1H, d, J = 8.1 Hz, H8),
7.27 (2H, d, J = 8.1, H-7, H-11); 13C NMR (125 MHz, CDCl3) δ 20.6 (C-15), 20.8 (C-13), 22.2 (C-12), 25.3
(C-14), 31.2 (C-4), 33.5 (C-5), 47.7 (C-2), 48.4 (C-1), 63.6 (C-3), 126.5 (C-7, C-11), 128.5 (C-8, C-10), 135.4
(C-9), 143.0 (C-6).
3.4. Transformaction of Natural Sesquiterpenes 1 and 2
Laurinterol (1, 8.0 mg, 0.027 mmol) was dissolved in ethyl ether (5 mL) and bromine (100 µL,
1.95 mmol) was added. The reaction was left under magnetic stirring for 15 min at room temperature,
after which the solvent was evaporated in vacuo. The reaction mixture was purified on a silica gel
0.2–0.5 mm (Sigma-Aldrich, St. Louis, MO, USA) column (10 Ø × 50 mm) using a step gradient
of n-Hex/EtOAc (100:0–95:5) to yield 8-bromoaplysin (6, 1.49 mg, 14.8%) and 7 (3.45 mg, 29.6%).
Similarly, isolaurinterol (2, 5.0 mg, 0.017 mmol) was treated with bromine (100 µL, 1.95 mmol) in the
same experimental conditions. After evaporation of the solvent, the reaction mixture was purified on a
silica gel column (10 Ø × 50 mm; step gradient of n-Hex/EtOAc (100:0–95:5)) to give compound 6
(1.32 mg, 23.5%), 8 (0,38 mg, 6%) and 9 (1.81 mg, 27.3%).
Laurinterol (1, 10.0 mg, 0.034 mmol) was dissolved in ethyl ether (5 mL) and HBr (10 µL, 48%)
was added. The reaction was left under magnetic stirring for 15 min at room temperature, after which
the solvent was evaporated in vacuo. Quantitative conversion was observed to aplysin (3) which was
purified by crystallization in n-hexane.
3.4.1. 8-Bromoaplysin (6)
Colorless oil; [α]20D −30 (c 0.12, CHCl3); IR υmax 3264, 1652, 1315, 1103, 1022, 904 cm−1; HREIMS
[M]+ m/z 371.9711 (calc. for C15H18O79Br2, 371.9724), 373.9702 (calc. for C15H18O79Br81Br, 373.9704),
375.9677 (calc. for C15H18O81Br2, 375.9683); 1H and 13 C NMR data (Table 1).
3.4.2. 3α-Bromojohnstane (7)
Colorless oil; [α]20D −35 (c 0.19, CHCl3); IR υmax 3259, 2362, 2158, 2031, 1975, 906, 800 cm−1;
HREIMS [M]+ m/z 449.8840 (calc. for C15H17O79Br3, 449.8829), 451.8800 (calc. for C15H17O79Br281Br,
451.8809), 453.8798 (calc. for C15H17O79Br81Br2, 453.8789), 455.8758 (calc. for C15H17O81Br3, 455.8768);
1H and 13 C NMR data (Table 2).
3.4.3. 8,10-Dibromoisoaplysin (8)
Colorless oil; [α]20D −17 (c 0.04, CHCl3); HREIMS [M]+ m/z 449.8836 (calc. for C15H17O79Br3,
449.8829), 451.8815 (calc. for C15H17O79Br281Br, 451.8809), 453.8783 (calc. for C15H17O79Br81Br2,
453.8789), 455.8764 (calc. for C15H17O81Br3, 455.8768).
3.4.4. 8,10-Dibromoaplysinol (9)
Colorless oil; [α]20D −6 (c 0.08, CHCl3); HREIMS [M]+ m/z 387.9680 (calc. for C15H18O279Br2,
387.9674), 389.9667 (calc. for C15H18O279Br81Br, 389.9653), 391.9639 (calc. for C15H18O281Br2, 391.9633).
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3.5. Cell Culture
The amoeba strain used in this study was the type strain: Acanthamoeba castellanii Neff (ATCC
30010) which was axenically grown in PYG medium (0.75% (w/v) proteose peptone, 0.75% (w/v) yeast
extract and 1.5% (w/v) glucose) containing 40 µg/mL of gentamicin (Biochrom AG, Cultek, Granollers,
Barcelona, Spain).
The murine macrophages J774A.1 (ATCC# TIB-67) cell line was cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum at 37 ◦C and 5% CO2 atmosphere, was used for the
cytotoxicity assays.
3.6. Anti-Acanthamoeba Activity
To evaluate the biological activity of the fractions and molecules, the anti-Acanthamoeba assays
were determined using the alamarBlue® method as previously described [15,16]. Firstly, Acanthamoeba
strain was seeded in triplicate on a 96-well microtiter plates with 50 µL from a stock solution of
104 cells/mL. Amoebae were left to adhere to the bottom of the well for 15 min, which was checked
using a Leika DMIL inverted microscope (Leika, Wetzlar, Germany). After that, 50 µL of serial
dilutions of the molecules were added to the wells (1% DMSO was used to dissolve the highest dose of
the compounds with no effects on the parasites). As a control, we use chlorhexidine (chlorhexidine
digluconate; Alfa Aesar), which is a standard antiseptic belonging to the biguanide family of antiseptics
that is commonly used in contact lens maintenance solutions; and voriconazole (Sigma) is an inhibitor
of ergosterol synthesis that has been proven previously to be highly effective against clinical strains of
Acanthamoeba [26,27]. Finally, the alamarBlue Reagent® (Life Technologies, Madrid, Spain) was placed
into each well at an amount equal to 10% of the final volume. Then, plates containing alamarBlue®
were incubated for 96 h at 26 ◦C with a slight agitation.
3.7. Cytotoxicity Test
The cytotoxicity assay was carried out using the alamarBlue® method as previously described [15,16].
Firstly, the macrophages were seeded in triplicate on a 96-well microtiter plates with 50 µL from a stock
solution of 2 × 105 cells/mL. Macrophages were left to adhere to the bottom of the well for 15 min,
which was checked using a Leika DMIL inverted microscope (Leika, Wetzlar, Germany). After that,
50 µL of serial dilutions of the molecules were added to the wells. Finally, the alamarBlue Reagent®
(Life Technologies, Madrid, Spain) was placed into each well at an amount equal to 10% of the final
volume. Then, plates containing alamarBlue® were incubated for 24 h at 37 ◦C in presence of CO2 at 5%.
3.8. Statical Analysis
Briefly, the test plates were analyzed, during an interval of time between 24 and 96 h, on an
EnSpire® Multimode Plate Reader (Perkin Elmer, Madrid, Spain) using fluorescence, a test wavelength
of 570 nm and a reference wavelength of 630 nm. The percentage of the growth inhibition, 50%
inhibitory concentration (IC50 or CC50) was calculated by linear regression analysis with 95%
confidence limits using Sigma Plot 12.0 statistical analysis software (Systat Software). All experiments
were performed three times, and the mean values were also calculated. A paired two-tailed t-test was
used for analysis of the data. Values of p < 0.05 were considered significant.
4. Conclusions
To the best of our knowledge, red algae have never been evaluated as a potential source
of amoebicidal agents. Furthermore, this is the first time that the anti-Acantamoeba activity of
the brominated sesquiterpenes α-bromocuparane (4) and α-isobromocuparane (5), isolated from
Laurencia johnstonii, is reported. On the other hand, after chemical modification of the inactive
metabolites laurinterol (1) and isolaurinterol (2), a set of brominated derivatives, 6–9, that substantially
improve the activity of the natural sesquiterpenes have been obtained. The addition of a second
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bromine atom in the aromatic ring of 6–9 seems to be relevant to increase the antiamoeboid activity.
Whereas all obtained derivatives possess a laurane-type framework, the most active compound,
3α-bromojohnstane (7), possesses a different rearranged carbon skeleton, johnstane, never found
among natural sesquiterpene metabolites isolated from Laurencia species so far. Our results suggest
that Laurencia-based brominated sesquiterpenes could be a potential source of novel therapeutic agents
against Acanthamoeba in the near future.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1660-3397/16/11/
443/s1. Scheme S1: Isolation process of sesquiterpenes 1–5 from Laurencia johnstonii; Figure S1:1H-NMR spectrum
for laurinterol (1); Figure S2: 1H-NMR spectrum for isolaurinterol (2); Figure S3: 1H-NMR spectrum for aplysin (3);
Figure S4: 1H-NMR spectrum for α-bromocuparane (4); Figure S5: 1H-NMR spectrum for α-isobromocuparane
(5); Figure S6: 1H-NMR spectrum of 8-bromoaplysin (6); Figure S7: COSY spectrum of 8-bromoaplysin (6); Figure
S8: HSQC-ed spectrum of 8-bromoaplysin (6); Figure S9: HMBC spectrum of 8-bromoaplysin (6); Figure S10:
13C NMR spectrum of 8-bromoaplysin (6); Figure S11: HREIMS spectrum of 8-bromoaplysin (6); Figure S12: 1H
NMR spectrum of 3α-bromojohnstane (7); Figure S13: COSY spectrum of 3α-bromojohnstane (7); Figure S14:
HSQC-ed spectrum of 3α-bromojohnstane (7); Figure S15: HMBC spectrum of 3α-bromojohnstane (7); Figure S16:
13C NMR spectrum of 3α-bromojohnstane (7); Figure S17: 1D-NOE experiments of 3α-bromojohnstane (7); Figure
S18: HREIMS spectrum of 3α-bromojohnstane (7); Figure S19: 1H NMR spectrum of 8,10-dibromoisoaplysin 8;
Figure S20: 1H NMR spectrum of 8,10-dibromoaplysinol 9.
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